As a Potential Oncogene and a Prognostic Biomarker for Neuroblastoma

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Oct 14

PMID 36237324

Authors

Jingjing Song

Chao Ni

Xubin Dong

Chenang Sheng

Yue Qu

Libin Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Neuroblastoma is the most common malignant extracranial tumor for children. Molecular mechanisms underpinning the pathogenesis of this disease are yet to be fully clarified. This study aimed to identify a novel oncogene that could be used as a biomarker informing the prognosis of neuroblastoma, and to predict its biological functions, using bioinformatics and molecular biology tools.

Methods: Three data sets from the TARGET, GSE62564, and GSE85047 databases were used for analysis. Survivals of patients with high or low expression of were compared, using the Kaplan-Meier curve and log-rank test. Immune infiltration was evaluated using ESTIMATE and MCP-counter algorithms. Synthetic small interfering RNAs (siRNAs) were employed to silence expression in neuroblastoma cell lines SH-SY5Y and SK-N-SH, in order to characterize its biological functions. Gene enrichment analyses of were carried out, using Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses.

Results: Expression of was found to significantly affect overall survival and event-free survival of patients with neuroblastoma, positively correlate with the expressions of and the gene, and negatively correlate with host immune infiltration. Expression of was elevated in patients with neuroblastoma. Silencing expression using siRNAs in SH-SY5Y and SK-N-SH resulted in decreased cell growth ( < 0.05), reduced migration ( < 0.05), and increased apoptosis ( < 0.05). Function analysis of revealed cancer-promoting effects, probably regulating several important downstream molecules, including that related to the apoptosis process and epithelial-mesenchymal transition.

Conclusion: We identified a potential tumor-promoting gene for neuroblastoma that could also serve as a prognostic biomarker.

Citing Articles

BUB1 as a novel marker for predicting the immunotherapy efficacy and prognosis of breast cancer.

Zhou R, Liu M, Li M, Peng Y, Zhang X Transl Cancer Res. 2024; 13(9):4534-4554.

PMID: 39430818 PMC: 11483447. DOI: 10.21037/tcr-24-704.

Sudden unexpected postnatal collapse and BUB1B mutation: first forensic case report.

Esposito M, Sessa F, Nannola C, Pignotti M, Greco P, Salerno M Int J Legal Med. 2024; 138(5):2049-2055.

PMID: 38664248 PMC: 11306263. DOI: 10.1007/s00414-024-03231-1.

Expression of the checkpoint kinase BUB1 is a predictor of response to cancer therapies.

Ciciro Y, Ragusa D, Sala A Sci Rep. 2024; 14(1):4461.

PMID: 38396175 PMC: 10891059. DOI: 10.1038/s41598-024-55080-y.

Inhibition of the serine/threonine kinase BUB1 reverses taxane resistance in prostate cancer.

Martinez M, Lyles R, Peinetti N, Grunfeld A, Burnstein K iScience. 2023; 26(9):107681.

PMID: 37705955 PMC: 10495664. DOI: 10.1016/j.isci.2023.107681.

References

Goswami S, Sharma-Walia N . Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis. BMC Cancer. 2015; 15:935. PMC: 4660791. DOI: 10.1186/s12885-015-1837-1. View

Irwin M, Park J . Neuroblastoma: paradigm for precision medicine. Pediatr Clin North Am. 2014; 62(1):225-56. DOI: 10.1016/j.pcl.2014.09.015. View

Medina M, Wandosell F . Deconstructing GSK-3: The Fine Regulation of Its Activity. Int J Alzheimers Dis. 2011; 2011:479249. PMC: 3100567. DOI: 10.4061/2011/479249. View

Dhillon S . Dinutuximab: first global approval. Drugs. 2015; 75(8):923-7. DOI: 10.1007/s40265-015-0399-5. View

Stuhlmiller T, Garcia-Castro M . Current perspectives of the signaling pathways directing neural crest induction. Cell Mol Life Sci. 2012; 69(22):3715-37. PMC: 3478512. DOI: 10.1007/s00018-012-0991-8. View

Brodeur G, Green A, Hayes F, Williams K, Williams D, Tsiatis A . Cytogenetic features of human neuroblastomas and cell lines. Cancer Res. 1981; 41(11 Pt 1):4678-86. View

Schliekelman M, Cowley D, OQuinn R, Oliver T, Lu L, Salmon E . Impaired Bub1 function in vivo compromises tension-dependent checkpoint function leading to aneuploidy and tumorigenesis. Cancer Res. 2009; 69(1):45-54. PMC: 4770788. DOI: 10.1158/0008-5472.CAN-07-6330. View

Cahill D, Lengauer C, Yu J, Riggins G, WILLSON J, Markowitz S . Mutations of mitotic checkpoint genes in human cancers. Nature. 1998; 392(6673):300-3. DOI: 10.1038/32688. View

Williams B, Amon A . Aneuploidy: cancer's fatal flaw?. Cancer Res. 2009; 69(13):5289-91. PMC: 2917070. DOI: 10.1158/0008-5472.CAN-09-0944. View

10.

Rashid M, Mazur T, Ji W, Liu S, Taylor W . Analysis of the role of GSK3 in the mitotic checkpoint. Sci Rep. 2018; 8(1):14259. PMC: 6155330. DOI: 10.1038/s41598-018-32435-w. View

11.

Mao Y, Keller E, Garfield D, Shen K, Wang J . Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 2012; 32(1-2):303-15. PMC: 4432936. DOI: 10.1007/s10555-012-9415-3. View

12.

Domingo-Fernandez R, Watters K, Piskareva O, Stallings R, Bray I . The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis. Pediatr Surg Int. 2013; 29(2):101-19. PMC: 3557462. DOI: 10.1007/s00383-012-3239-7. View

13.

Schmidt M, Lal A, Seeger R, Maris J, Shimada H, OLeary M . Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2005; 23(27):6474-80. DOI: 10.1200/JCO.2005.05.183. View

14.

. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3):676-90. PMC: 4243044. DOI: 10.1016/j.cell.2014.09.050. View

15.

Hsu C, Chen Y, Su H, Huang G, Shu C, Tong-Lin Wu T . Targeting TPX2 Suppresses the Tumorigenesis of Hepatocellular Carcinoma Cells Resulting in Arrested Mitotic Phase Progression and Increased Genomic Instability. J Cancer. 2017; 8(8):1378-1394. PMC: 5479243. DOI: 10.7150/jca.17478. View

16.

Mosse Y, Laudenslager M, Longo L, Cole K, Wood A, Attiyeh E . Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008; 455(7215):930-5. PMC: 2672043. DOI: 10.1038/nature07261. View

17.

Finetti P, Cervera N, Charafe-Jauffret E, Chabannon C, Charpin C, Chaffanet M . Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res. 2008; 68(3):767-76. DOI: 10.1158/0008-5472.CAN-07-5516. View

18.

Trigg R, Shaw J, Turner S . Opportunities and challenges of circulating biomarkers in neuroblastoma. Open Biol. 2019; 9(5):190056. PMC: 6544987. DOI: 10.1098/rsob.190056. View

19.

Huang M, Weiss W . Neuroblastoma and MYCN. Cold Spring Harb Perspect Med. 2013; 3(10):a014415. PMC: 3784814. DOI: 10.1101/cshperspect.a014415. View

20.

Siegel D, King J, Tai E, Buchanan N, Ajani U, Li J . Cancer incidence rates and trends among children and adolescents in the United States, 2001-2009. Pediatrics. 2014; 134(4):e945-55. PMC: 4536809. DOI: 10.1542/peds.2013-3926. View